Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
Completed · Phase 2 · Has a placebo group
Conditions studied: Polycystic Ovary Syndrome
In brief
The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.
Key facts
- Study ID
- NCT03152591
- Run by
- Novartis Pharmaceuticals
- People needed
- 29
- Starts
- 2017-07-24
- Expected to finish
- 2018-06-25
- Last updated by the study team
- 2021-01-05
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Springfield, Missouri, United States
- Novartis Investigative Site — Philadelphia, Pennsylvania, United States
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Freiburg im Breisgau, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.